This Biotech Company Could Change the IVF Process for People Like Me – SheKnows

One of the most challenging aspects of assisted reproductive technology is the lack of a clear path to build a family. Evaluations by reproductive endocrinologists, diagnostics, procedures, and luck all play a role in the process. When my husband and I began trying to start a family, we faced the news that I had low levels of Anti-Mullerian Hormone (AMH). We opted for in vitro fertilization (IVF) and found ourselves navigating a complex, unknown process. After experiencing setbacks and emotional turmoil, I eventually had success with IVF and now have two sons and am pregnant with our third child. However, the financial burden and absence of adequate insurance coverage for IVF treatments are major challenges for many women. That’s why I’m excited about a biotechnology company called Oviva Therapeutics, which is developing a drug to improve ovarian function and extend female healthspan. This drug could potentially increase the success rate of IVF treatments, reduce the number of cycles needed, and cut back on the overall investment of IVF. As someone who faced these challenges firsthand, I joined Oviva as COO to work on a product that could positively impact women struggling with infertility. I wish I had known about the community and educational resources offered by organizations like Conceive earlier in my journey. Getting a second opinion, understanding out-of-pocket costs upfront, taking breaks when needed, and seeking therapy are all crucial aspects of navigating the IVF process. With these tools and resources, we can better support women facing the challenges of infertility. This Biotech Company Could Change the IVF Process for People Like Me – SheKnows